Turning Point Therapeutics, Inc. (TPTX)
Stock Price:
$61.22 USD
-1.56 (-2.48%)
Updated Jul 9, 2020 2:51 PM EDT - Market open
Key Info
| Market Cap |
2.20B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-119.30M |
| Shares Out |
41.34M |
| EPS (ttm) |
-3.70 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 9, 2020 |
| Last Price |
$61.22 |
| Previous Close |
$62.77 |
| Change ($) |
-1.56 |
| Change (%) |
-2.48% |
| Day's Open |
63.01 |
| Day's Range |
59.57 - 63.66 |
| Day's Volume |
148,329 |
| 52-Week Range |
31.30 - 72.03 |
More Stats
| Market Cap |
2.20B |
| Enterprise Value |
1.82B |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
41.34M |
| Float |
25.80M |
| EPS (basic) |
-3.47 |
| EPS (diluted) |
-3.70 |
| FCF / Share |
-2.16 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.74M |
| Short Ratio |
4.72 |
| Short % of Float |
9.43% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.97 |
| Revenue |
n/a |
| Operating Income |
-126.29M |
| Net Income |
-119.30M |
| Free Cash Flow |
-77.60M |
| Net Cash |
376.02M |
| Net Cash / Share |
10.47 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-23.81% |
| ROE |
-51.03% |
| ROIC |
-41.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$79.50*
(29.87% upside)
Low
67.0
Current: 61.22
High
88.0
Target: 79.50
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -77.72 | -25.64 | -16.73 |
| Net Income | -72.13 | -24.79 | -16.59 |
| Shares Outstanding | 24.12 | 3.39 | 3.34 |
| Earnings Per Share | -2.99 | -7.31 | -4.97 |
| Operating Cash Flow | -57.76 | -23.53 | -12.64 |
| Capital Expenditures | -1.74 | -0.30 | -0.09 |
| Free Cash Flow | -59.50 | -23.84 | -12.73 |
| Cash & Equivalents | 409 | 101 | 45.03 |
| Total Debt | 5.06 | - | - |
| Net Cash / Debt | 404 | 101 | 45.03 |
| Assets | 422 | 103 | 45.91 |
| Liabilities | 17.85 | 152 | 70.75 |
| Book Value | 404 | -48.41 | -24.84 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Turning Point Therapeutics, Inc. |
| Country |
United States |
| Employees |
102 |
| CEO |
Athena Countouriotis |
Stock Information
| Ticker Symbol |
TPTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TPTX |
| IPO Date |
October 4, 2006 |
Description
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.